CADD is a cutting-edge computational method used to locate and develop a promising lead in the drug discovery process. Molecular modelling, molecular design, computational chemistry, and rational drug design are all components of computer-aided drug design. To maximise discovered leads, CADD is being employed. Both in academic communities and the pharmaceutical companies, CADD approaches are becoming more well-liked and respected. Time is saved, and the CADD technique is quick and economical. The four steps of the CADD method are as follows: (1) use a virtual screening (VS) protocol to screen a small molecule library against the target to find hits or leads, (2) examine the specificity of the selected hits from VS using molecular docking in the active site of other recognized targets, and (3) predict ADMET properties of the selected hit using in silico techniques and the most promising hits are referred to as leads and step four assists in optimizing the leads by creating better compounds for synthesis and testing. Structure-based and ligand-based drug design are the two categories into which CADD approaches are divided depending on the availability of the target protein's 3D structure (SBDD and LBDD). The pharmacological target's 3D structure is necessary for SBDD. The target structure can be obtained in one of two ways: (1) by downloading it from the Protein Data Bank (PDB) if the protein structure has been solved by crystallography and (2) employ molecular modeling (a bioinformatics technique) to forecast the structure if the protein structure cannot be determined.
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Precision diagnostics: Effectiveness of innovative imaging technologies for early detection of lung cancers
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Design and characterization of gum arabic buccal films for protein drug delivery
Krisztian Pamlenyi, University of Szeged, Hungary
Title : Advancing EGFR-targeting macrocyclic peptide-drug conjugates to target KRAS-mutant solid tumors: Design, synthesis, and preclinical evaluations
Akash Panja, Ariel University, Israel